Jacob P. Thyssen, Steffen Heegaard, Lena Ivert, Anita Remitz, Tove Agner, Marjolein De Bruin-Weller, Theis Huldt-Nystrøm, Laura Korhonen, Lina U. Ivert, Pekka Leinonen, Johanna Mandelin, Tore Särnhult, Thomas Schopf, Eirik Sundlisæter, Simon F. Thomsen, Thrasyvoulos Tzellos, Christian Vestergaard, Laura von Kobyletzki, Maria Bradley
DOI: 10.2340/00015555-3629

There is a need for unified guidance on the management of ocular manifestations of atopic dermatitis and ocular manifestations associated with dupilumab in the Nordic region (Denmark, Finland, Norway and Sweden). This initiative gathered Nordic dermatologists and ophthalmologists to identify consensus in this area using a modified Delphi process. The initiative was led by a Nordic expert panel who developed a questionnaire that was circulated to a wider group. The results informed an agenda consisting of 24 statements to be voted on using a 5-point Likert scale at a meeting in Copenhagen on 24 April 2019. A facilitator moderated discussion and revised statements according to expert feedback for a second vote when required to reach consensus. Consensus was reached for 23 statements regarding the diagnosis, treatment and referral of these patients, which we hope will improve patient management in the Nordic region.

There is a need for guidance on the management of ocular manifestations of atopic dermatitis and ocular manifestations associated with dupilumab in the Nordic region (Denmark, Finland, Norway and Sweden). Nordic dermatologists and ophthalmologists worked together to identify consensus in this area, using a modified Delphi process, which involved voting on the extent to which the audience agreed with a series of statements. Consensus was reached for 22 of the 24 statements regarding the diagnosis, treatment and referral of these patients, which we hope will improve patient management in the Nordic region.

Figure S1
Figure S1